LIPELLA PHARMACEUTICALS INC. 8-K

What Happened

• Lipella Pharmaceuticals Inc. (ticker: LIPO) announced it and certain of its subsidiaries (the “Debtors”) have filed voluntary petitions for relief under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania. The company filed the Form 8‑K on March 31, 2026; a related press release is dated March 30, 2026.

Key Details

• The filing covers Lipella and certain subsidiaries as the Debtors seeking reorganization under Chapter 11.
• The Chapter 11 cases were filed in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
• The company cautioned that trading its common stock during the Chapter 11 cases is “highly speculative” and that market prices may bear little or no relation to any eventual recovery for stockholders.
• The 8‑K includes a press release dated March 30, 2026 (filed as Exhibit 99.1).

Why It Matters

• Chapter 11 is a formal bankruptcy process that typically involves restructuring the company’s debts while operations may continue under court supervision. For retail investors, the filing means substantial uncertainty about the value of Lipella common stock: the company itself warns that trading is highly speculative and that holders may recover little or nothing. Expect further court filings and company disclosures that will determine the timeline and potential outcomes for creditors and equity holders.